Company

Oncodesign

Headquarters: Dijon, France

Employees: 226

CEO: Dr. Philippe Genne

Euronext: ALONC

Market Cap

€99.7 Million

EUR as of Dec. 1, 2022

US$105.0 Million

Market Cap History

Oncodesign market capitalization over time

Evolution of Oncodesign market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Oncodesign

Detailed Description

Oncodesign Société Anonyme, a biopharmaceutical company, conducts research and development work on new therapeutic and diagnostic tools with pharmaceutical firms, biotech companies, public research institutions, and investment groups. It offers integrated drug discovery services; in vitro and in vivo pharmacology services; services for studying the metabolism and pharmacokinetics of drug candidates; and translational biomarkers, biodecontamination/biosafety, and biobanking services. The company also engages in the analysis of new chemical and biological entities, and membrane proteins; and immuno analysis and monitoring, and microbiological monitoring activities. In addition, it engages in the kinase inhibitor development programs, and licensing of Kinase inhibitors in oncology, and CNS and inflammation technologies. Oncodesign Société Anonyme has a strategic partnership with InterSystems for new treatments in the field of oncology; and Covalab. The company also has a collaboration agreement with TiumBio Co., Ltd. for the research and development of fibrosis drug candidates. Oncodesign Société Anonyme was founded in 1995 and is headquartered in Dijon, France.

Top 1-year algo backtest: +298.72%

$10,000 in April 2023 would now be $39,872 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Oncodesign has the following listings and related stock indices.


Stock: Euronext: ALONC wb_incandescent

Details

Headquarters:

20 rue Jean Mazen

BP 27627 Cedex

Dijon, 21076

France

Phone: 33 3 80 78 82 60

Fax: 33 3 80 78 82 61